Emyria (ASX:EMD) Sees 10% Surge on Promising Interim Results for MDMA-Assisted Therapy in PTSD Treatment

2 min read | September 02, 2024 11:05 AM AEST | By Team Kalkine Media

Google News:

Emyria (ASX:EMD) Sees 10% Surge on Promising Interim Results for MDMA-Assisted Therapy in PTSD Treatment — Image source: Shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

On Monday, shares of Emyria (ASX:EMD) experienced a notable 9.4% increase, reaching 3.5 cents per share, following the announcement of positive interim results from their MDMA-assisted psychotherapy trials for PTSD patients.

The interim data revealed that eight patients undergoing MDMA therapy, administered in conjunction with a professional therapist, showed "substantial improvement" in their PTSD symptoms. This improvement was self-reported by the patients, suggesting enhancements in their overall quality of life.

Emyria’s interim results indicate that MDMA therapy not only provides immediate symptom relief but may also foster long-term psychological improvements. Although detailed patient feedback metrics were not disclosed, the study included both male and female participants with an average age of 45 years.

The treatment protocol, as outlined by Emyria, involves a comprehensive 10 to 16-week program. This includes over 90 hours of therapeutic sessions and specialist consultations, alongside MDMA dosages. The interim data is based on two to three therapy sessions.

Emyria’s full program spans 2 to 4 months, incorporating multiple therapeutic sessions and addressing potential dependence issues that may arise. The company's approach aims to offer a broader and more durable solution for PTSD care beyond controlled clinical settings.

According to Michael Winlo, CEO of Emyria, the preliminary results underscore the significant potential of MDMA-assisted therapy for treating PTSD and provide valuable insights into its effectiveness in real-world clinical settings. With Australia being the sole jurisdiction currently allowing these therapies under strict regulations, Emyria is strategically positioned to lead the global advancement and refinement of this treatment modality. The company is focused on accumulating crucial real-world data and enhancing the therapy to maximize its therapeutic benefits.

As Emyria progresses with its research and development, the results of this interim report highlight the promising future of MDMA-assisted therapy in addressing PTSD and other mental health conditions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.